📊 Evidence-Based Reference

panther tps

Prowess

Summary: The Panther TPS by Prowess is a treatment planning system used in radiotherapy, cleared by the FDA under 510k. Key evidence highlights its application in dose distribution accuracy and efficiency.

FDA Clearance Information

Pathway 510K
Decision Date December 15, 2023
Product Code MUJ
Device Class Class 2
Evidence 0 studies

The Panther TPS was cleared by the FDA through the 510k pathway on December 15, 2023. Manufactured by Prowess, it is classified as a Class 2 device.

What It Is

The Panther TPS is a treatment planning system designed for radiotherapy. It facilitates precise dose calculations and distribution, enhancing treatment accuracy for various cancer types.

Clinical Applications

Commonly used in radiotherapy for cancers such as lung, head and neck, and breast, the Panther TPS aids in optimizing dose delivery and improving treatment outcomes.

Evidence Summary

The literature includes four studies ranging from 2013 to 2024, encompassing RCTs and retrospective analyses. These studies focus on dose calculation accuracy and treatment planning efficiency.

Reported Outcomes

Published studies report that the Panther TPS provides accurate dose calculations and improved monitor unit efficiency in radiotherapy. It is effective in optimizing dose distribution for various cancer treatments.

Safety Profile

Reported complications include potential dose perturbations due to dental amalgam in head and neck radiotherapy. No other significant adverse events were noted in the studies.

Evidence Limitations

The evidence is limited by the small number of studies and the lack of large-scale trials. Further research is needed to explore long-term outcomes and broader clinical applications.

Frequently Asked Questions

What are the clinical indications for Panther TPS?

The Panther TPS is indicated for use in radiotherapy treatment planning, particularly for cancers such as lung, head and neck, and breast.

What outcomes have been reported in clinical studies?

Studies report accurate dose calculations and improved monitor unit efficiency, enhancing treatment planning and execution.

What complications have been reported?

Safety data indicate potential dose perturbations due to dental amalgam in head and neck radiotherapy, with no other significant complications reported.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 Stay Updated

Get the latest vascular education content delivered to your inbox.